Abstract
The human androgen receptor (AR) is expressed in nearly all prostate cancers (PCa) and is known to participate in tumor progression through the expression of genes involved in the proliferation and differentiation of PCa. It is suggested that different types of ligands induce a distinct AR conformation that would lead to a specific set of interacting partners for the AR, such as coactivators (CoA) and corepressors (CoR), heat shock proteins (HSP), remodeling factors, kinases, phosphatases, and transcription factors resulting in various degrees of AR activity and stability. The natural ligand of the AR, dihydrotestosterone (DHT), induces a transcriptionally active conformation of the AR while the steroidal antiandrogen cyproterone acetate (CPA) and the nonsteroidal compounds hydroxyflutamide (OHF), bicalutamide (Cas), and atraric acid (AA) prevent acquisition of a transcriptionally active conformation. The AR has, in addition to transactivation, other functional properties. However, the current known interaction partners of AR cannot explain the multitude of AR-mediated functions. Thus, many of the ligand-specific AR-interacting proteins still remain unidentified. Here we provide an assay system to assess AR interactions in LNCaP PCa cells. LNCaP cells were treated with the AR-agonist R1881 or AR-antagonists Cas or AA to induce ligand-specific cofactor (CoF) binding to the AR in vivo. Here we describe a method for the identification of ligand-selective interaction partners of AR combining immunological methods with surface-enhanced laser desorption/ionization (SELDI)–time of flight (TOF)–mass spectrometry (MS). Exemplified here is the interaction of a novel AR-CoF, the cell-cycle regulating protein cell division cycle-associated protein 2 (CDCA2) with AR in the presence of antagonist which is verified by a protein–protein interaction assay in vivo. This scheme can provide further insights into the molecular mechanisms of AR ligand selectivity.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Jemal, A. (2009) Cancer statistics. CA Cancer J. Clin. 59 (4), 225–249 (2009).
Andriole, G., Bruchovsky, N., Chung, L.W., Matsumoto, A.M., Rittmaster, R., Roehrborn, C., Russell, D., Tindall, D. (2004) Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J. Urol. 172 (4 Pt 1), 1399–1403.
Ross, R., Bernstein, L., Judd, H., Hanisch, R., Pike, M., Henderson, B. (1986) Serum testosterone levels in healthy-young black-and-white men. J. Natl. Cancer Inst. 76, 45–48.
Evans, R.M. (1988) The steroid and thyroid-hormone receptor superfamily. Science 240, 889–895.
Culig, Z., Klocker, H., Bartsch, G., Hobisch, A. (2002) Androgen receptors in prostate cancer. Endocr. Relat. Cancer 9, 155–170.
Papaioannou, M., Schleich, S., Prade, I., Degen, S., Roell, D., Schubert, U., Tanner, T., Claessens, F., Matusch, R., Baniahmad, A. (2009) The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth. J. Cell. Mol. Med. 13 (8B), 2210–2223.
Li, J., Al-Azzawi, F. (2009) Mechanism of androgen receptor action. Maturitas 63, 142–148.
Kim, J., Coetzee, G.A. (2004) Prostate specific antigen gene regulation by androgen receptor. J. Cell. Biochem. 93 (2), 233–241.
Lemon, B.D., Freedman, L.P. (1999) Nuclear receptor CoF as chromatin remodelers. Curr. Opin. Genet. Dev. 9, 499–504.
Xu, L., Glass, C.K., Rosenfeld, M.G. (1999) Coactivator and corepressor complexes in nuclear receptor function. Curr. Opin. Genet, Dev. 9, 140–147.
Eisoldt, M., Asim, M., Eskelinen, H., Linke, T., Baniahmad, A. (2009) Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens. J. Mol. Endocrinol. 42, 429–435.
Glass, C.K., Rosenfeld, M.G. (2000) The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14, 121–141.
Farla, P., Hersmus, R., Trapman, J., Houtsmuller, A.B. (2005) Antiandrogens prevent stable DNA-binding of the androgen receptor. J. Cell. Sci. 118, 4187–4198.
Hodgson, M.C., Astapova, I., Cheng, S., Lee, L.J., Verhoeven, M.C., Choi, E., Balk, S.P., Hollenberg, A.N. (2005) The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J. Biol. Chem. 280, 6511–6519.
Masiello, D., Cheng, S., Bubley, G.J., Lu, M.L., Balk, S.P. (2002) Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J. Biol. Chem. 277, 26321–26326.
Zhu, W., Smith, A., Young, C.Y. (1999) A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology 140 (11), 5451–5454.
von Eggeling, F., Junker, K., Fiedle, W., Wollscheid, V., Dürst, M., Claussen, U., Ernst, G. (2001) Mass spectrometry meets chip technology: a new proteomic tool in cancer research? Electrophoresis 22 (14), 2898–2902.
Abramovitz, M., Leyland-Jones, B. (2006) A systems approach to clinical oncology: focus on breast cancer. Proteome Sci. 4, 4–5.
Miyamae, T., Malehorn, D.E., Lemster, B., Mori, M., Imagawa, T., Yokota, S., Bigbee, W.L., Welsh, M., Klarskov, K., Nishomoto, N., Vallejo, A.N., Hirsch, R. (2005) Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy. Arthritis Res. Ther. 7 (4), R746–R755.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Linke, T., Scholten, M., Baniahmad, A. (2011). Detection of Ligand-Selective Interactions of the Human Androgen Receptor by SELDI-MS-TOF. In: Saatcioglu, F. (eds) Androgen Action. Methods in Molecular Biology, vol 776. Humana Press. https://doi.org/10.1007/978-1-61779-243-4_14
Download citation
DOI: https://doi.org/10.1007/978-1-61779-243-4_14
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-242-7
Online ISBN: 978-1-61779-243-4
eBook Packages: Springer Protocols